Women with early invasive breast cancer who underwent one-week high- or low-dose hypofractionated adjuvant whole-breast radiotherapy regimen had similar five-year ipsilateral breast tumor relapse rates and safety outcomes, compared with those who received the standard three-week regimen, according to a study presented at the European Society for Radiology and Oncology 2020 Online Congress and published in The Lancet. The findings suggest the safety and efficacy of hypofractionated radiotherapy regimen as the new standard for early invasive breast cancer, said researcher Joanne Haviland.